Treatment of RAF1-Related Obstructive Hypertrophic Cardiomyopathy by MEK Inhibition Using Trametinib

Treatment of RAF1-Related Obstructive Hypertrophic Cardiomyopathy by MEK Inhibition Using Trametinib

RASopathies cause nonsarcomeric hypertrophic cardiomyopathy via dysregulated signaling through RAS and upregulated mitogen-activated protein kinase activity. We provide the first report of the successful treatment of an adult with RAF1-associated hypertrophic cardiomyopathy using trametinib, a MEK i...

Full description

Bibliographic Details
Main Authors: Omid Kiamanesh, MD, Steven C. Greenway, MD, Franciscus Dicke, MD, MBA, Brennan Ballantyne, MD, Sasha Mitrovic, RDCS, Kaitlin McGrath, MD, James A. White, MD, William D.T. Kent, MD, Gregor Andelfinger, MD
Format: Article
Language:English
Published: Elsevier 2024-07-01
Series:JACC: Case Reports
Subjects:
cardiovascular genetics
hypertrophic cardiomyopathy
Noonan syndrome
RASopathies
Online Access:http://www.sciencedirect.com/science/article/pii/S2666084924001724

Internet

http://www.sciencedirect.com/science/article/pii/S2666084924001724

Similar Items